Ocala, FL 的 脂肪性肝病 臨床試驗
8 項針對 脂肪性肝病 的研究正在 Ocala（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
招募中3 期
- 89bio Clinical Study Site, Ocala
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
招募中3 期
- 89bio Clinical Study Site, Ocala
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
招募中3 期
- GSK Investigational Site, Ocala
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
招募中3 期
- GSK Investigational Site, Ocala
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
招募中3 期
- Akero Clinical Study Site, Ocala
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
招募中3 期
- GSK Investigational Site, Ocala
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
招募中2 期
- Ocala GI Research, Ocala
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
招募中3 期
- GSK Investigational Site, Ocala
其他城市的 脂肪性肝病 試驗
- San Antonio, TX17 項研究
- Miami, FL16 項研究
- New York City, NY16 項研究
- San Diego, CA14 項研究
- Austin, TX13 項研究
- Houston, TX13 項研究
- Richmond, VA12 項研究
- Tucson, AZ10 項研究
- Chandler, AZ10 項研究
- Orlando, FL9 項研究
- St. Louis, MO9 項研究
- Dallas, TX9 項研究
Ocala 的其他研究
- 非小細胞肺癌10 項研究
- 肥胖症7 項研究
- 過重6 項研究
- 阿茲海默症6 項研究
- 心臟衰竭5 項研究
- 慢性阻塞性肺病5 項研究
- 肝臟疾病3 項研究
- 慢性疼痛3 項研究
- 輕度認知障礙3 項研究
- 轉移性癌症3 項研究
- 心血管疾病3 項研究
- 動脈硬化3 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。